Drug intelligence / Profile preview

SER-603

Development stage: Preclinical
Lead developer: Seres Therapeutics
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

SER-603 is a novel cultivated live biotherapeutic product candidate developed by Seres Therapeutics. It is currently in preclinical development for the treatment of Inflammatory Bowel Disease (IBD), including ulcerative colitis and Crohn's disease. Seres Therapeutics received an award from the Crohn's & Colitis Foundation's IBD Ventures program to support its preclinical development.

Beyond the preview

Go deeper on SER-603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-603.

Explore the full profile